Shearman & Sterling advised Ibere Pharmaceuticals, a blank check company formed for the purpose of effecting a merger in the pharmaceutical and life sciences industries, in its $138 million initial public offering. Ibere Pharmaceuticals is listed on the New York Stock Exchange and commenced trading on February 26, 2021 under the ticker symbol "IBERU."

The Team